Skip to main content

Table 2 Multivariate analysis of pre-transplant factors predicting for NRM, relapse, and chronic GVHD

From: Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation

 

NRM

Relapse

Chronic GVHD

Factor

HR

(95 % CI)

P value

HR

(95 % CI)

P value

HR

(95 % CI)

P value

RIC vs. MAC

0.56

(0.43–0.74)

0.0004

1.19

(0.95–1.49)

0.13

1.19

(0.95–1.49)

0.12

CR2 vs. CR1

1.35

(0.96–1.90)

0.09

1.68

(1.26–2.23)

0.0004

1.10

(0.82–1.46)

0.53

Advanced vs. CR1

1.61

(1.19–2.17)

0.002

2.71

(2.17–3.38)

<0.00001

1.42

(1.08–1.85)

0.01

In vivo T cell depletion

0.85

(0.62–1.17)

0.33

1.35

(1.09–1.68)

0.01

0.62

(0.49–0.80)

0.0002

Age > 55 years

1.46

(1.13–1.89)

0.004

1.45

(1.13–1.89)

0.0004

1.00

(0.82–1.23)

0.99

F → M

1.41

(1.09–1.83)

0.01

1.03

(0.83–1.28)

0.78

1.11

(0.89–1.38)

0.37

Cytogenetics

 Intermediate vs. good

0.73

(0.46–1.16)

0.18

1.70

(1.01–2.86)

0.05

0.76

(0.53–1.11)

0.16

 Poor vs. good

0.63

(0.35–1.13)

0.12

3.36

(1.94–5.84)

0.0002

0.71

(0.45–1.11)

0.13

 Missing

0.77

(0.46–1.27)

0.31

1.67

(0.96–2.91)

0.07

0.78

(0.51–1.21)

0.27

Year of SCT

0.96

(0.91–1.01)

0.12

0.98

(0.93–1.02)

0.30

1.01

(0.97–1.06)

0.58

Patient CMV +

1.22

(0.92–1.61)

0.17

0.94

(0.75–1.17)

0.56

0.99

(0.80–1.23)

0.95

Donor CMV +

0.88

(0.68–1.14)

0.33

1.03

(0.84–1.27)

0.79

0.98

(0.80–1.21)

0.87

PBSC vs. BM

0.90

(0.66–1.24)

0.53

0.80

(0.61–1.05)

0.10

1.45

(1.08–1.95)

0.01

  1. Abbreviations: as in Table 1. NRM non-relapse mortality, BM bone marrow